Sarepta Therapeutics Inc (SRPT)

01:39 AM

A Look At Sarepta Therapeutics (SRPT) Valuation After Elevidys Launch Updates And Recovery Story Analyst Commentary - simplywall.st

01:39 AM

Mar 04, 2026

(SRPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Mar 04, 2026

Mar 04, 2026

SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026

Mar 03, 2026

Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026 - Meyka

Mar 03, 2026

Mar 03, 2026

Sarepta (SRPT) COO Estepan reports PSU vesting and tax share withholding - Stock Titan

Mar 03, 2026

Mar 03, 2026

SRPT: 2026 revenue targets remain solid as clinical and commercial initiatives advance toward 2027 - TradingView

Mar 03, 2026

Mar 03, 2026

SRPT SEC FilingsSarepta Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 03, 2026

Mar 03, 2026

Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty - TipRanks

Mar 03, 2026

Mar 03, 2026

Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight - GuruFocus

Mar 03, 2026

Mar 02, 2026

Sarepta Therapeutics Eyes 2026 Reset After Rocky Year - TipRanks

Mar 02, 2026

Mar 02, 2026

Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo Finance

Mar 02, 2026

Mar 02, 2026

Wedbush Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $29.00 - MarketBeat

Mar 02, 2026

Mar 02, 2026

Wedbush Adjusts Sarepta Therapeutics PT to $29 From $34, Maintains Outperform Rating - marketscreener.com

Mar 02, 2026

Mar 02, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright - MarketBeat

Mar 02, 2026

Mar 02, 2026

Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Vanguard Group Inc. - MarketBeat

Mar 02, 2026

Mar 02, 2026

Sarepta (NASDAQ: SRPT) COO exercises stock options, lifts holdings to 200,750 shares - Stock Titan

Mar 02, 2026

Mar 02, 2026

Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Understanding the 25.56% Upside Potential - DirectorsTalk Interviews

Mar 02, 2026

Mar 02, 2026

HC Wainwright & Co. Reiterates Sell Rating for SRPT | SRPT Stock News - GuruFocus

Mar 02, 2026

Mar 02, 2026

Sarepta Therapeutics 10-K: $2.20B Revenue, $(7.13) EPS - TradingView

Mar 02, 2026

Mar 02, 2026

Sarepta (NASDAQ: SRPT) details 2025 gene therapy setbacks and big siRNA deal - Stock Titan

Mar 02, 2026

Mar 02, 2026

Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance

Mar 02, 2026

Mar 02, 2026

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Mar 02, 2026

Mar 01, 2026

Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 - Yahoo Finance

Mar 01, 2026

Feb 28, 2026

Why Sarepta Therapeutics (SRPT) Is Down 11.2% After CEO Retirement Plan And Japan Gene Therapy LaunchAnd What's Next - Yahoo Finance

Feb 28, 2026

Feb 28, 2026

Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Sahm

Feb 28, 2026

Feb 28, 2026

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey

Feb 28, 2026

Feb 28, 2026

Is Sarepta Therapeutics (SRPT) Pricing Reflect Its Value After Recent Share Price Slide - simplywall.st

Feb 28, 2026

Feb 28, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Feb 28, 2026

Feb 27, 2026

Sarepta (SRPT) COO earns 1,875 PSUs tied to performance milestones - Stock Titan

Feb 27, 2026

Feb 27, 2026

Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $38.00 - MarketBeat

Feb 27, 2026

Feb 27, 2026

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Yahoo Finance

Feb 27, 2026

Feb 27, 2026

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 27, 2026

Feb 27, 2026

Erste Asset Management GmbH Has $50.59 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Feb 27, 2026

Feb 27, 2026

Sarepta Therapeutics CEO Ingram to retire by year end - The Mighty 790 KFGO

Feb 27, 2026

Feb 26, 2026

Sarepta Therapeutics Announces Planned CEO Leadership Transition - The Globe and Mail

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics (SRPT) Q4 Loss Deepens And Tests Bullish Profitability Narrative - simplywall.st

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings - MarketBeat

Feb 26, 2026

Feb 26, 2026

After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral - BioSpace

Feb 26, 2026

Feb 26, 2026

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates - Nasdaq

Feb 26, 2026

Feb 26, 2026

Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO - Pharmaceutical Executive

Feb 26, 2026

Feb 26, 2026

Sarepta CEO Ingram Steps Down As Dystrophy Strikes Close To Home - Citeline News & Insights

Feb 26, 2026

Feb 26, 2026

Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 26, 2026

Feb 26, 2026

Sarepta to present Duchenne therapy data at MDA conference By Investing.com - Investing.com South Africa

Feb 26, 2026

Feb 26, 2026

Sarepta to present Duchenne therapy data at MDA conference - Investing.com

Feb 26, 2026

Feb 26, 2026

Sarepta seeks new boss amid Doug Ingram retirement - The Pharma Letter

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 26, 2026

Feb 26, 2026

Sarepta CEO Doug Ingram to retire, with company at a crossroads - BioPharma Dive

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics Reports Earnings Miss and Management Transition - Intellectia AI

Feb 26, 2026

Feb 26, 2026

Sarepta CEO To Jump Ship After 'Tumultuous' YearSarepta Therapeutics (NASDAQ:SRPT) - Benzinga

Feb 26, 2026

Feb 26, 2026

Rhumbline Advisers Sells 88,893 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments - BioSpace

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SRPT) 2026-02-26 - Seeking Alpha

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics Q4 Earnings Call Highlights - MarketBeat

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics (SRPT) CEO Announces Retirement Amid Stock Decline - GuruFocus

Feb 26, 2026

Feb 26, 2026

Sarepta Therapeutics Inc (SRPT) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Challenges - GuruFocus

Feb 26, 2026

Feb 25, 2026

Fed. Circ. Gene Therapy Ruling Gives Rare Eligibility Clarity - Law360

Feb 25, 2026

Feb 25, 2026

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits

Feb 25, 2026

Feb 25, 2026

Sarepta Therapeutics (SRPT) Projects Strong 2026 with Robust Pip - GuruFocus

Feb 25, 2026

Feb 25, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Posts Earnings Results, Misses Expectations By $2.71 EPS - MarketBeat

Feb 25, 2026

Feb 25, 2026

Sarepta CEO Doug Ingram to retire by year-end - FirstWord Pharma

Feb 25, 2026

Feb 25, 2026

Sarepta (SRPT) CEO Douglas Ingram Announces Retirement Plan - GuruFocus

Feb 25, 2026

Feb 25, 2026

Sarepta CEO to retire - TipRanks

Feb 25, 2026

Feb 25, 2026

Sarepta (SRPT) Q4 2025 Earnings Call Transcript - The Globe and Mail

Feb 25, 2026

Feb 25, 2026

Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home - BioSpace

Feb 25, 2026

Feb 25, 2026

Sarepta Q4 2025 slides: revenue beats, profitability path outlined By Investing.com - Investing.com South Africa

Feb 25, 2026

Feb 25, 2026

Sarepta CEO to Retire by Year-End to Spend Time With Sick Family - Bloomberg.com

Feb 25, 2026